Eckert & Ziegler Strahlen- und Medizintechnik AG

Earnings Release • Aug 4, 2009

News Details

Corporate | 4 August 2009 07:43

Eckert & Ziegler continues on record course. Strongest half year in company history.

Eckert & Ziegler Strahlen- und Medizintechnik AG / Half Year Results/Forecast

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 04.08.2009. In the first half of 2009 the Berlin based Eckert &
Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist
for isotope technology in medicine, science and industry, the Eckert &
Ziegler Group set new records with sales of EUR 52 million and Group
profits of EUR 4 million, thus far exceeding the existing operative
records. Compared with last year's period, sales increased by EUR 20
million, or 60%. Compared with the 1st half of 2008, the profit after tax
and minority interests more than doubled when the special effect resulting
from the IBt consolidation is excluded. The operative cash flow achieved
EUR 6.5 million and also set a new record. Earnings per share of EUR 1.08
were posted in the first half of the year.

Revenues in the Therapy Segment rose by 41%, driven primarily by strong
afterloader sales in Eastern Europe, which doubled in comparison to last
year. An additional push to revenues resulted from sales to IBt's new joint
venture in Russia. In the Nuclear Imaging and Industry segment, sales
almost doubled from EUR 14.4 million to EUR 26.3 million. This resulted
from the combined effects of the inclusion of Nuclitec sales, increased
sales in robust drill hole sources, and a USD exchange rate improvement of
13%. Despite the loss of sales in Italy, the Radiopharmaceuticals segment
grew by 42%. The two main product categories, Modular-Lab and diagnostics
for positron emission tomography (PET), continued their growth trend from
the previous quarters. Added to this were Nuclitec's initial aurigamedical
sales.

The Nuclear Imaging and Industry segment was still the main source of
sales, just as in previous periods. Sales have increased by 83%.
Approximately half of that, i.e. 41% growth, can be seen in profits after
tax, which have increased by EUR 0.9 million compared with the same period
last year and which now stand at EUR 3.2 million. Profits show that
Nuclitec has been integrated successfully and is already a profitable
factor. For the first time since the inclusion of IBt, the Therapy segment
was able to show a clear profit. In proportion to revenues, the EUR 2.9
million EUR in half year net profits now represent the highest profit
margin of all segments. Furthermore, the new Russian project already
increased profits in the second quarter and is expected to increase them
further in the second half of the year.

The Radiopharmaceuticals segment continues posted a profit of EUR 0.2
million despite high launch costs for new products. Small gains from the
deconsolidation of the Italian stake further increased profits.
For the current year, the company expects sales of approx. EUR 100 million
and earnings per share of approx. EUR 1.80.
Eckert & Ziegler AG is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine and has 524
employees.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations,
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de
04.08.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, ISIN DE0005659700
WKN: 565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg

End of News DGAP News-Service

---